Cargando…

Muscle wasting in myotonic dystrophies: a model of premature aging

Myotonic dystrophy type 1 (DM1 or Steinert’s disease) and type 2 (DM2) are multisystem disorders of genetic origin. Progressive muscular weakness, atrophy and myotonia are the most prominent neuromuscular features of these diseases, while other clinical manifestations such as cardiomyopathy, insulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateos-Aierdi, Alba Judith, Goicoechea, Maria, Aiastui, Ana, Fernández-Torrón, Roberto, Garcia-Puga, Mikel, Matheu, Ander, López de Munain, Adolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496580/
https://www.ncbi.nlm.nih.gov/pubmed/26217220
http://dx.doi.org/10.3389/fnagi.2015.00125
_version_ 1782380429950582784
author Mateos-Aierdi, Alba Judith
Goicoechea, Maria
Aiastui, Ana
Fernández-Torrón, Roberto
Garcia-Puga, Mikel
Matheu, Ander
López de Munain, Adolfo
author_facet Mateos-Aierdi, Alba Judith
Goicoechea, Maria
Aiastui, Ana
Fernández-Torrón, Roberto
Garcia-Puga, Mikel
Matheu, Ander
López de Munain, Adolfo
author_sort Mateos-Aierdi, Alba Judith
collection PubMed
description Myotonic dystrophy type 1 (DM1 or Steinert’s disease) and type 2 (DM2) are multisystem disorders of genetic origin. Progressive muscular weakness, atrophy and myotonia are the most prominent neuromuscular features of these diseases, while other clinical manifestations such as cardiomyopathy, insulin resistance and cataracts are also common. From a clinical perspective, most DM symptoms are interpreted as a result of an accelerated aging (cataracts, muscular weakness and atrophy, cognitive decline, metabolic dysfunction, etc.), including an increased risk of developing tumors. From this point of view, DM1 could be described as a progeroid syndrome since a notable age-dependent dysfunction of all systems occurs. The underlying molecular disorder in DM1 consists of the existence of a pathological (CTG) triplet expansion in the 3′ untranslated region (UTR) of the Dystrophia Myotonica Protein Kinase (DMPK) gene, whereas (CCTG)n repeats in the first intron of the Cellular Nucleic acid Binding Protein/Zinc Finger Protein 9 (CNBP/ZNF9) gene cause DM2. The expansions are transcribed into (CUG)n and (CCUG)n-containing RNA, respectively, which form secondary structures and sequester RNA-binding proteins, such as the splicing factor muscleblind-like protein (MBNL), forming nuclear aggregates known as foci. Other splicing factors, such as CUGBP, are also disrupted, leading to a spliceopathy of a large number of downstream genes linked to the clinical features of these diseases. Skeletal muscle regeneration relies on muscle progenitor cells, known as satellite cells, which are activated after muscle damage, and which proliferate and differentiate to muscle cells, thus regenerating the damaged tissue. Satellite cell dysfunction seems to be a common feature of both age-dependent muscle degeneration (sarcopenia) and muscle wasting in DM and other muscle degenerative diseases. This review aims to describe the cellular, molecular and macrostructural processes involved in the muscular degeneration seen in DM patients, highlighting the similarities found with muscle aging.
format Online
Article
Text
id pubmed-4496580
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44965802015-07-27 Muscle wasting in myotonic dystrophies: a model of premature aging Mateos-Aierdi, Alba Judith Goicoechea, Maria Aiastui, Ana Fernández-Torrón, Roberto Garcia-Puga, Mikel Matheu, Ander López de Munain, Adolfo Front Aging Neurosci Neuroscience Myotonic dystrophy type 1 (DM1 or Steinert’s disease) and type 2 (DM2) are multisystem disorders of genetic origin. Progressive muscular weakness, atrophy and myotonia are the most prominent neuromuscular features of these diseases, while other clinical manifestations such as cardiomyopathy, insulin resistance and cataracts are also common. From a clinical perspective, most DM symptoms are interpreted as a result of an accelerated aging (cataracts, muscular weakness and atrophy, cognitive decline, metabolic dysfunction, etc.), including an increased risk of developing tumors. From this point of view, DM1 could be described as a progeroid syndrome since a notable age-dependent dysfunction of all systems occurs. The underlying molecular disorder in DM1 consists of the existence of a pathological (CTG) triplet expansion in the 3′ untranslated region (UTR) of the Dystrophia Myotonica Protein Kinase (DMPK) gene, whereas (CCTG)n repeats in the first intron of the Cellular Nucleic acid Binding Protein/Zinc Finger Protein 9 (CNBP/ZNF9) gene cause DM2. The expansions are transcribed into (CUG)n and (CCUG)n-containing RNA, respectively, which form secondary structures and sequester RNA-binding proteins, such as the splicing factor muscleblind-like protein (MBNL), forming nuclear aggregates known as foci. Other splicing factors, such as CUGBP, are also disrupted, leading to a spliceopathy of a large number of downstream genes linked to the clinical features of these diseases. Skeletal muscle regeneration relies on muscle progenitor cells, known as satellite cells, which are activated after muscle damage, and which proliferate and differentiate to muscle cells, thus regenerating the damaged tissue. Satellite cell dysfunction seems to be a common feature of both age-dependent muscle degeneration (sarcopenia) and muscle wasting in DM and other muscle degenerative diseases. This review aims to describe the cellular, molecular and macrostructural processes involved in the muscular degeneration seen in DM patients, highlighting the similarities found with muscle aging. Frontiers Media S.A. 2015-07-09 /pmc/articles/PMC4496580/ /pubmed/26217220 http://dx.doi.org/10.3389/fnagi.2015.00125 Text en Copyright © 2015 Mateos-Aierdi, Goicoechea, Aiastui, Fernández-Torrón, Garcia-Puga, Matheu and López de Munain. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Mateos-Aierdi, Alba Judith
Goicoechea, Maria
Aiastui, Ana
Fernández-Torrón, Roberto
Garcia-Puga, Mikel
Matheu, Ander
López de Munain, Adolfo
Muscle wasting in myotonic dystrophies: a model of premature aging
title Muscle wasting in myotonic dystrophies: a model of premature aging
title_full Muscle wasting in myotonic dystrophies: a model of premature aging
title_fullStr Muscle wasting in myotonic dystrophies: a model of premature aging
title_full_unstemmed Muscle wasting in myotonic dystrophies: a model of premature aging
title_short Muscle wasting in myotonic dystrophies: a model of premature aging
title_sort muscle wasting in myotonic dystrophies: a model of premature aging
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496580/
https://www.ncbi.nlm.nih.gov/pubmed/26217220
http://dx.doi.org/10.3389/fnagi.2015.00125
work_keys_str_mv AT mateosaierdialbajudith musclewastinginmyotonicdystrophiesamodelofprematureaging
AT goicoecheamaria musclewastinginmyotonicdystrophiesamodelofprematureaging
AT aiastuiana musclewastinginmyotonicdystrophiesamodelofprematureaging
AT fernandeztorronroberto musclewastinginmyotonicdystrophiesamodelofprematureaging
AT garciapugamikel musclewastinginmyotonicdystrophiesamodelofprematureaging
AT matheuander musclewastinginmyotonicdystrophiesamodelofprematureaging
AT lopezdemunainadolfo musclewastinginmyotonicdystrophiesamodelofprematureaging